Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.
The purpose of this study is to determine if RAD001 (everolimus) helps improve the standard treatment of XELOX-A (bevacizumab, oxaliplatin, capecitabine) in advanced solid tumors.
Unspecified Adult Solid Tumor, Protocol Specific|Cancer
DRUG: capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)
To determine the MTD/RPTD of capecitabine/oxaliplatin/bevacizumab/everolimus (XELOX-A-Ev) for subjects with advanced solid tumors., End of treatment phase
Describe dose-limiting and non-dose-limiting toxicities, End of treatment phase|preliminarily investigate the response rate and PFS, from response to progression
The purpose of this study is to determine if RAD001 (everolimus) helps improve the standard treatment of XELOX-A (bevacizumab, oxaliplatin, capecitabine) in advanced solid tumors.